Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206

Leukemia and Lymphoma

Volumn 48, Issue 7, 2007, Pages 1313-1319

  Blum, Kristie A ^a   Johnson, Jeffrey L ^b   Niedzwiecki, Donna ^b   Canellos, George P ^c   Cheson, Bruce D ^d   Bartlett, Nancy L ^e  

^a OHIO STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Bortezomib; Hodgkin lymphoma; Refractory; Relapsed

Indexed keywords

ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; BILIRUBIN; BORTEZOMIB; HYPERTENSIVE FACTOR; INFUSION FLUID;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COUGHING; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DYSPNEA; FEMALE; HODGKIN DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERBILIRUBINEMIA; HYPOTENSION; HYPOXIA; INFECTION; LEUKOPENIA; LUNG INFILTRATE; LUNG TOXICITY; LYMPHOCYTOPENIA; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; BORONIC ACIDS; DISEASE PROGRESSION; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; PYRAZINES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT FAILURE;

EID: 34447566086     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701411458     Document Type: Article

References (35)

1. Jost, P. and Ruland, J. (2007) Aberrant NF-κB signaling in lymphoma: Mechanisms, consequences, and therapeutic implications. Blood
2. Bargou, R. C., Leng, C., Krappmann, D., Emmerich, F., Mapara, M. Y., Bommert, K., Royer, H. D., Scheidereit, C. and Dorken, B. (1996) High-level nuclear NF-κB and Oct-2 is a common feature of cultured Hodgkin/Reed - Sternberg cells. Blood, 87, pp. 4340-4347.
3. Krappmann, D., Emmerich, F., Kordes, U., Sherschmidt, E., Dorken, B. and Scheidereit, C. (1999) Molecular mechanisms of constitutive NF-κB/ Rel activation in Hodgkin/Reed - Sternberg cells. Oncogene, 18, pp. 943-953.
4. Staudt, L. M. (2000) The molecular and cellular origins of Hodgkin's disease. J Exper Med, 191, pp. 207-212.
5. Heckman, C., Mehew, J. and Boxer, L. (2002) NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells. Oncogene, 21, pp. 3898-3908.
6. Davis, R. E., Conne, B., Chappuis, R., Berczy, M., Mhauech, P., Staudt, L. M. and Schwaller, J. (2005) MALT1 and the API2-MALT1 fusion act between CD40 and IKK and confer NF-{κ}B-dependent proliferative advantage and resistance against FAS-induced cell death in B cells. Blood, 105, pp. 2891-2899.
7. Davis, R., Brown, K., Siebenlist, U. and Staudt, L. (2001) Constitutive nuclear factor κB activity is required for survival of activated B-cell like diffuse large B cell lymphoma cells. J Exp Med, 194, pp. 1861-1874.
8. Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H. D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H. and Dorken, B. (1999) Overexpression of I κBα without inhibition of NF-κB activity and mutations in the I κBα gene in Reed - Sternberg cells. Blood, 94, pp. 3219-3234.
9. Horie, R., Watanabe, T., Morishita, Y., Ishida, Y., Kanegae, Y., Saito, I., Higashihara, M., Mori, S., Kadin, M. E. and Watanabe, T. (2002) Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin - Reed - Sternberg cells. Oncogene, 21, pp. 2493-2503.
10. Fiumara, P., Snell, V., Mukhopadhyay, A., Younes, M., Gillenwater, A. M., Cabanilles, F., Aggarwal, B. B. and Younes, A. (2001) Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood, 98, pp. 2784-2790.
11. Darnay, B., Haridas, V., Moore, P. and Aggarwal, B. (1998) Characterization of the intracellular domain of receptor activator of NF-κB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J Biol Chem, 273, pp. 20551-20555.
12. Grech, A., Amesbury, M., Chan, T., Gardam, S., Basten, A. and Brink, R. (2004) TRAF2 differentially regulates the canonical and noncanonical pathways of NF-κB activation in mature B cells. Immunity, 21, pp. 629-642.
13. Eliopoulos, A., Caamano, J., Flavell, J., Reynods, G. M., Murray, P. G., Poyet, J. L. and Young, L. S. (2003) Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NF-κB2 to p52 via an IKK γ/NEMO-independent signaling pathway. Oncogene, 22, pp. 7557-7569.
14. Hinz, M., Loser, P., Mathas, S., Krappmann, D., Dorken, B. and Sheidereit, C. (2001) Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed - Sternberg cells. Blood, 97, pp. 2798-2807.
15. Izban, K. F., Ergin, M., Huang, Q., Qin, J. Z., Martinez, R. L., Schnitzer, B., Nickoloff, B. J. and Alkan, S. (2001) Characterization of NF-κB expression in Hodgkin's disease: Inhibition of constitutively expressed NF-κB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed - Sternberg cells. Modern Pathol, 14, pp. 297-310.
16. Zheng, B., Georgakis, G., Bhart, A., McConkey, D., Aggarwal, B. B. and Younes, A. (2004) Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin Disease cell lines is independent of inhibitor of nuclear factor-κB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res, 10, pp. 3207-3215.
17. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P. G., Niesvizky, R., Alexanian, R., Limentani, S. A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D. L., Schenkein, O. P. and Anderson, K. C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol, 127, pp. 165-172.
18. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagganath, S., Irwin, D., Roykumar, S. V., Srkalovic, J., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D-L, Kaufmann, M., Adams, J., Shenkein, D. P. and Anderson, K. C. (2003) A Phase 2 Study of Bortezomib in relapsed, refractory myeloma. N Engl J Med, 348, pp. 2609-2617.
19. Goy, A., Younes, A., McLaughlin, P., Pro, B., Romaguerra, J. E., Hagemeister, F., Fayad, L., Dang, N. H., Samaniego, F., Wang, M., Broglio, K., Samuels, B., Giles, F., Sarris, A. G., Hart, S., Trehu, S., Schenkein, D., Cabanillas, F. and Rodriguez, A. M. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol, 23, pp. 667-675.
20. O'Connor, O. A., Wright, J., Moskowitz, C., Muzzy, J., MacGregor-Cortelli, B., Stubblefield, M., Straus, D., Portlock, C., Hamlin, P., Choi, E., Dumetrescu, B., Esseltine, D., Trehu, E., Adams, J., Schenkein, D. and Zelentz, A. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol, 23, pp. 676-684.
21. Fisher, R. I., Bernstein, S. H., Kahl, B. S., Djulbegovic, B., Robertson, M. J., de Vos, S., Epner, E., Krishnan, A., Leonard, J. P., Lonial, S., Stadtmauer, E. A., O'Connor, O. A., Shi, H., Boral, A. L. and Goy, A. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol, 24, pp. 4867-4874.
22. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N. L., Armitage, J. O., Carter, W., Hoppe, R. and Canellos, G. P. (1999) Report of an international report to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
23. Santor, A., Bredenfeld, H., Devizzi, L., Tesch, H., Bonfante, V., Viviani, S., Fiedler, F., Parra, H. S., Benoehr, C., Pacini, M., Bonadonna, G. and Diehl, V. (2000) Gemcitabine in the treatment of refractory Hodgkin's disease: Results of a multicenter phase II study. J Clin Oncol, 18, pp. 2615-2619.
24. Devizzi, L., Santoro, A., Bonfante, V., Viviani, S., Balzarini, L., Valagussa, P. and Bonadonna, G. (1994) Vinorelbine: An active drug for the management of patients with heavily pretreated Hodgkin's disease. Ann Oncol, 5, pp. 817-820.
25. Younes, A., Pro, B. and Fayad, L. (2006) Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood, 107, pp. 1731-1732.
26. Cabannes, E., Khan, G., Aillet, F., Jarrett, R. and Hay, R. (1999) Mutations in IκBα gene in Hodgkin's disease suggest a tumor suppressor role for IκBα. Oncogene, 18, pp. 3063-3070.
27. Emmerich, F., Theurich, S., Hummel, M., Haeffker, A., Vry, M. S., Dohner, K., Bommert, K., Stein, H. and Dorken, B. (2003) Inactivating IκB epsilon mutations in Hodgkin Reed - Sternberg cells. J Pathol, 201, pp. 413-420.
28. Jungnickel, B., Staratschek-Jox, A., Brauninger, A., Spieker, T., Wolf, J., Diehl, V., Hansmann, M. L., Rajewskly, K. and Kuppers, R. (2000) Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J Exp Med, 191, pp. 395-402.
29. Joos, S., Menz, C., Wrobel, G., Siebert, R., Gesk, S., Ohl, S., Mechtersheimer, G., Trumper, L., Moller, P., Lichter, P. and Barth, T. F. (2002) Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood, 99, pp. 1381-1387.
30. Martin-Subero, J., Gesk, S., Harder, L., Sonoki, T., Tucker, P. W., Schlegelberger, B., Grote, W., Novo, F. J., Calasanz, M. J., Hansmann, M. L., Dyer, M. J. and Seibert, R. (2002) Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood, 99, pp. 1474-1477.
31. Barth, T., Martin-Subero, J., Joos, S., Menz, C. K., Hasel, C., Mechtersheimer, G., Parwaresch, R. M., Lichter, P., Siebert, R. and Mooler, P. (2003) Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood, 101, pp. 3681-3686.
32. Boll, B., Hansen, H., Heuck, F., Reiners, K., Borchmann, P., Rothe, A., Engert, A. and von Strandmann, E. P. (2005) The fully human anti-CD30 antibody 5F11 activates NF-κB and sensitizes lymphoma cells to bortezomib-induced apoptosis. Blood, 106, pp. 1839-1842.
33. Kashkar, H., Deggerich, A., Seeger, J-M, Yazdanpanah, B., Wiegmann, K., Haubert, D., Pongratz, C. and Kronke, M. (2007) NF-κB independent down-regulation of XIAP by bortezomib sensitizes HL B-cells against cytotoxic drugs. Blood, 109, pp. 3982-3988.
34. Sterz, J., Jakob, C., Kuckelkorn, U., Braun, H. A., Kaiser, M., Fleissner, C., Kleeberg, L., Heider, U., Possinger, K., Kloetzel, P. M., Sezer, O. and Zavrski, I. (2006) BSc2118, a novel proteasome inhibitor, shows anti-tumor activity in multiple myeloma and mantle cell lymphoma. Blood, 108, p. 3475.
35. O'Connor, O. A., Orlowski, R. Z., Alsina, M., Steward, K., Trudel, S., Wallone, M. K., Woo, T. M., Urquilla, P. R., Molineaux, C. J. and Goy, A. (2006) Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematologic malignancies. Blood, 108, p. 2430.